Best Weight Loss Drug Stocks to Buy in 2026

The article highlights strong GLP-1 demand, with Eli Lilly's Mounjaro sales up 125% in Q1 2026 and Zepbound up 80%, while Novo Nordisk's GLP-1 pill is gaining traction but faces pricing and patent headwinds. Eli Lilly remains the category leader, but the piece argues Novo Nordisk may offer a better risk-reward setup at 10x P/E versus Eli Lilly at 35x P/E. Viking Therapeutics is framed as a high-risk, clinical-stage wildcard rather than a core holding.

Analysis

The market is increasingly pricing GLP-1s as a category winner-takes-most market, but the more important second-order dynamic is that this is evolving from a pure efficacy story into a distribution-and-persistence war. That favors the incumbent with the best launch cadence and manufacturing optionality, but it also creates a hidden barbell: premium multiple support for the leader while the value case shifts toward the laggard that can re-rate on any evidence of share recovery or margin stabilization. The real risk is that investors anchor on headline growth rates while missing how much of near-term revenue expansion is still capacity-constrained and therefore less durable than it appears.

Novo’s setup is interesting because the stock has effectively de-rated into a litigation/patent/pricing overhang, which means the market is already discounting a fairly severe slowdown. That makes the upside asymmetric if oral adoption broadens beyond early users, since pills reduce injection friction and can expand the addressable patient pool without requiring the same clinic-based activation. The contrarian view is that the current discount may be too deep relative to pipeline optionality and the probability that a cheaper entry point offsets margin pressure over the next 12 months.

For Lilly, the key issue is not whether it remains the category leader, but whether the multiple can hold if growth decelerates from exceptional to merely strong. At ~35x earnings, the stock needs continued execution plus a clean read-through on the pill to justify premium duration, and any manufacturing hiccup or payer pushback would likely compress the multiple before fundamentals roll over. That creates a classic quality-at-a-price risk: good business, poor forward return if expectations stay elevated.

Viking is a binary optionality trade, not an operating business trade. The stock can remain dead money for months, then gap materially on a clinical signal, but the probability-weighted outcome is poor unless a catalyst lands quickly. In this tape, the best use is as a small-call spread expression on positive trial data rather than a common-stock allocation.

Key Decisions for Investors

• Long NVO / short LLY as a 6-12 month relative-value pair: express the view that valuation mean reversion plus broadening oral adoption can close part of the gap if Lilly’s growth normalizes while Novo’s discount is too severe.
• If seeking outright exposure, buy NVO on weakness in tranches over the next 1-3 months; risk/reward improves if the market continues to overprice patent/pricing fears and ignores operating leverage from renewed demand.
• Avoid chasing LLY at current levels unless using a hedge: if long, pair with short basket exposure or buy downside puts 3-6 months out to guard against multiple compression from any growth miss.
• Use VKTX only as a defined-risk option structure, such as a 6-12 month call spread ahead of clinical catalysts; do not hold size in common equity given high burn and binary trial outcomes.
• For a cleaner sector expression, overweight NVO and underweight the broader healthcare growth basket for 2-4 quarters; the stock appears to embed more pessimism than the operating trajectory justifies.